胰腺癌患者冷冻消融治疗前后血清CD44v6和整合素阻的变化及在预后评估中的意义

摘要：目的探讨胰腺癌患者冷冻消融治疗前后血清中CD44v6及整合素β1表达水平的变化及与预后的相关性。方法44例胰腺癌患者行冷冻消融治疗术，收集患者治疗前后及20名正常人（对照组）的血清标本，采用酶联免疫吸附试验（ELISA）测定CD44v6及整合素B1在血清中的表达水平。结果与对照组比较，患者术前和术后10dCD44v6和整合素B1的表达水平均较高（P〈0．05），而术后1个月的表达水平与对照组差异无统计学意义（P〉0．05）；术后患者的CD44v6和整合素β1的表达水平均逐渐下降，术后1个月二者的表达水平均明显低于术前（P〈0．05）。CD44v6和整合素B1的表达水平与肿瘤大小、分化、临床分期、淋巴结转移及肝转移均明显相关（P〈O．05），而与患者性别、年龄及肿瘤位置均无相关性（P〉0．05）。CD44v6和整合素β1低表达患者术后的中位生存期分别为14．5个月和14．2个月，而高表达患者仅为9．5个月和9．8个月，二者间差异均有统计学意义（P〈0．05）。结论CD44v6和整合素81的血清表达水平与胰腺癌的发生、发展、转移及预后等密切相关。

The changes of serum CD44v6 and integrin beta 1 before and after cryosurgery in patients with pancreatic cancer and the significance in prognosis evaluation

Objective To investigate the changes of the expression levels of serum CD44v6 and integrin beta 1 in patients with pancreatic cancer before and after cryosurgery and the correlation between the expression levels and prognosis. Methods Cryosurgery was conducted in 44 patients with pancreatic cancer. Serum samples were collected from the patients before and after cryosurgery and 20 healthy subjects （control group）. Enzyme-linked immunosorbent assay （ELISA） was used to detect the expression levels of serum CD44v6 and integrin beta 1. Results Compared with the control group,the expression levels of CD44v6 and integrin beta 1 in patients before and after cryosurgery for 10 d were higher （P 〈 O. 05）. No statistical significance was found between the patients after cryosurgery for 1 month and the control group （P 〉 0.05 ）. The CD44v6 and integrin beta 1 expression levels decreased gradually after cryosurgery. The expression levels of CIM4v6 and integrin beta 1 in patients after cryosurgery for 1 month were significantly lower than those in patients before cryosurgery （P 〈 0.05 ）. Both CD44v6 and integrin beta 1 expression levels were significantly correlated with tumor size, tumor differentiation, clinical stage,lymph node metastasis and liver metastasis （ P 〈 0.05 ） , while they were not correlated with sex, age and tumor location （ P 〉 0.05 ）. The median survival times of patients with low CD44v6 and integrin beta 1 expressions were 14.5 months and 14.2 months, while those of patients with high CD44v6 and intergrin beta 1 expressions were only 9.5 months and 9.8 months. There were statistical significances （P 〈 0. 05 ）. Conclusions Serum CD44v6 and integrin beta 1 expression levels are closely correlated to the development, invasion, metastasis and prognosis of pancreatic cancer.